Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents: interim report
Gespeichert in:
| Format: | Elektronisch E-Book |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Washington, DC
The National Academies Press
[2003]
|
| Schlagworte: | |
| Online-Zugang: | FAW01 FAW02 Volltext |
| Beschreibung: | Title from title screen Version viewed January 9, 2015 |
| Beschreibung: | 1 online resource |
| ISBN: | 0309582598 1280247843 9780309582599 9781280247842 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043034939 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 151120s2003 |||| o||u| ||||||eng d | ||
| 020 | |a 0309582598 |9 0-309-58259-8 | ||
| 020 | |a 1280247843 |9 1-280-24784-3 | ||
| 020 | |a 9780309582599 |9 978-0-309-58259-9 | ||
| 020 | |a 9781280247842 |9 978-1-280-24784-2 | ||
| 035 | |a (OCoLC)58596199 | ||
| 035 | |a (DE-599)BVBBV043034939 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 |a DE-1047 | ||
| 082 | 0 | |a 615.9 |2 22 | |
| 245 | 1 | 0 | |a Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents |b interim report |c Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents, Medical Follow-up Agency and Board on Life Sciences, Institute of Medicine, and National Research Council of the National Academies |
| 264 | 1 | |a Washington, DC |b The National Academies Press |c [2003] | |
| 300 | |a 1 online resource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Title from title screen | ||
| 500 | |a Version viewed January 9, 2015 | ||
| 505 | 8 | |a Having the means to protect its military personnel against biological warfare agents is a long-standing objective for the United States. The development of safe and effective medical countermeasures -- vaccines, antitoxins, and prophylactic and therapeutic drugs -- against those agents is one of the essential components of the nation's biological defense efforts. Currently, the United States has a limited repertoire of licensed medical countermeasures that the Department of Defense (DoD) can use to protect members of the armed forces against more than a dozen bacteria, viruses, and toxins identified as possible biological warfare agents. As part of its Chemical and Biological Defense Program, DoD is engaged in research and development efforts aimed at making available a broader range of medical countermeasures | |
| 610 | 1 | 4 | |a United States / Department of Defense |
| 650 | 4 | |a Biological Warfare / prevention & control / United States | |
| 650 | 4 | |a Biological Warfare Agents / United States | |
| 650 | 4 | |a Civil Defense / methods / United States | |
| 650 | 4 | |a Military Medicine / methods / United States | |
| 650 | 4 | |a Toxicology | |
| 650 | 7 | |a MEDICAL / Toxicology |2 bisacsh | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Biological weapons |x Health aspects | |
| 651 | 4 | |a USA | |
| 710 | 2 | |a Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures against Biological Warfare Agents |e Sonstige |4 oth | |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123486 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-EBA | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028459588 | ||
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123486 |l FAW01 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
| 966 | e | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123486 |l FAW02 |p ZDB-4-EBA |q FAW_PDA_EBA |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175394221326336 |
|---|---|
| any_adam_object | |
| building | Verbundindex |
| bvnumber | BV043034939 |
| collection | ZDB-4-EBA |
| contents | Having the means to protect its military personnel against biological warfare agents is a long-standing objective for the United States. The development of safe and effective medical countermeasures -- vaccines, antitoxins, and prophylactic and therapeutic drugs -- against those agents is one of the essential components of the nation's biological defense efforts. Currently, the United States has a limited repertoire of licensed medical countermeasures that the Department of Defense (DoD) can use to protect members of the armed forces against more than a dozen bacteria, viruses, and toxins identified as possible biological warfare agents. As part of its Chemical and Biological Defense Program, DoD is engaged in research and development efforts aimed at making available a broader range of medical countermeasures |
| ctrlnum | (OCoLC)58596199 (DE-599)BVBBV043034939 |
| dewey-full | 615.9 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.9 |
| dewey-search | 615.9 |
| dewey-sort | 3615.9 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03231nmm a2200505zc 4500</leader><controlfield tag="001">BV043034939</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">151120s2003 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309582598</subfield><subfield code="9">0-309-58259-8</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1280247843</subfield><subfield code="9">1-280-24784-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309582599</subfield><subfield code="9">978-0-309-58259-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781280247842</subfield><subfield code="9">978-1-280-24784-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)58596199</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043034939</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield><subfield code="a">DE-1047</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.9</subfield><subfield code="2">22</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents</subfield><subfield code="b">interim report</subfield><subfield code="c">Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents, Medical Follow-up Agency and Board on Life Sciences, Institute of Medicine, and National Research Council of the National Academies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, DC</subfield><subfield code="b">The National Academies Press</subfield><subfield code="c">[2003]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Title from title screen</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Version viewed January 9, 2015</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Having the means to protect its military personnel against biological warfare agents is a long-standing objective for the United States. The development of safe and effective medical countermeasures -- vaccines, antitoxins, and prophylactic and therapeutic drugs -- against those agents is one of the essential components of the nation's biological defense efforts. Currently, the United States has a limited repertoire of licensed medical countermeasures that the Department of Defense (DoD) can use to protect members of the armed forces against more than a dozen bacteria, viruses, and toxins identified as possible biological warfare agents. As part of its Chemical and Biological Defense Program, DoD is engaged in research and development efforts aimed at making available a broader range of medical countermeasures</subfield></datafield><datafield tag="610" ind1="1" ind2="4"><subfield code="a">United States / Department of Defense</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological Warfare / prevention & control / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological Warfare Agents / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Civil Defense / methods / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Military Medicine / methods / United States</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Toxicology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological weapons</subfield><subfield code="x">Health aspects</subfield></datafield><datafield tag="651" ind1=" " ind2="4"><subfield code="a">USA</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures against Biological Warfare Agents</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123486</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028459588</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123486</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123486</subfield><subfield code="l">FAW02</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FAW_PDA_EBA</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| geographic | USA |
| geographic_facet | USA |
| id | DE-604.BV043034939 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:15:35Z |
| institution | BVB |
| isbn | 0309582598 1280247843 9780309582599 9781280247842 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028459588 |
| oclc_num | 58596199 |
| open_access_boolean | |
| owner | DE-1046 DE-1047 |
| owner_facet | DE-1046 DE-1047 |
| physical | 1 online resource |
| psigel | ZDB-4-EBA ZDB-4-EBA FAW_PDA_EBA |
| publishDate | 2003 |
| publishDateSearch | 2003 |
| publishDateSort | 2003 |
| publisher | The National Academies Press |
| record_format | marc |
| spelling | Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents interim report Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents, Medical Follow-up Agency and Board on Life Sciences, Institute of Medicine, and National Research Council of the National Academies Washington, DC The National Academies Press [2003] 1 online resource txt rdacontent c rdamedia cr rdacarrier Title from title screen Version viewed January 9, 2015 Having the means to protect its military personnel against biological warfare agents is a long-standing objective for the United States. The development of safe and effective medical countermeasures -- vaccines, antitoxins, and prophylactic and therapeutic drugs -- against those agents is one of the essential components of the nation's biological defense efforts. Currently, the United States has a limited repertoire of licensed medical countermeasures that the Department of Defense (DoD) can use to protect members of the armed forces against more than a dozen bacteria, viruses, and toxins identified as possible biological warfare agents. As part of its Chemical and Biological Defense Program, DoD is engaged in research and development efforts aimed at making available a broader range of medical countermeasures United States / Department of Defense Biological Warfare / prevention & control / United States Biological Warfare Agents / United States Civil Defense / methods / United States Military Medicine / methods / United States Toxicology MEDICAL / Toxicology bisacsh Medizin Biological weapons Health aspects USA Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures against Biological Warfare Agents Sonstige oth http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123486 Aggregator Volltext |
| spellingShingle | Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents interim report Having the means to protect its military personnel against biological warfare agents is a long-standing objective for the United States. The development of safe and effective medical countermeasures -- vaccines, antitoxins, and prophylactic and therapeutic drugs -- against those agents is one of the essential components of the nation's biological defense efforts. Currently, the United States has a limited repertoire of licensed medical countermeasures that the Department of Defense (DoD) can use to protect members of the armed forces against more than a dozen bacteria, viruses, and toxins identified as possible biological warfare agents. As part of its Chemical and Biological Defense Program, DoD is engaged in research and development efforts aimed at making available a broader range of medical countermeasures United States / Department of Defense Biological Warfare / prevention & control / United States Biological Warfare Agents / United States Civil Defense / methods / United States Military Medicine / methods / United States Toxicology MEDICAL / Toxicology bisacsh Medizin Biological weapons Health aspects |
| title | Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents interim report |
| title_auth | Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents interim report |
| title_exact_search | Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents interim report |
| title_full | Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents interim report Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents, Medical Follow-up Agency and Board on Life Sciences, Institute of Medicine, and National Research Council of the National Academies |
| title_fullStr | Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents interim report Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents, Medical Follow-up Agency and Board on Life Sciences, Institute of Medicine, and National Research Council of the National Academies |
| title_full_unstemmed | Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents interim report Committee on Accelerating the Research, Development, and Acquisition of Medical Countermeasures Against Biological Warfare Agents, Medical Follow-up Agency and Board on Life Sciences, Institute of Medicine, and National Research Council of the National Academies |
| title_short | Accelerating the research, development, and acquisition of medical countermeasures against biological warfare agents |
| title_sort | accelerating the research development and acquisition of medical countermeasures against biological warfare agents interim report |
| title_sub | interim report |
| topic | United States / Department of Defense Biological Warfare / prevention & control / United States Biological Warfare Agents / United States Civil Defense / methods / United States Military Medicine / methods / United States Toxicology MEDICAL / Toxicology bisacsh Medizin Biological weapons Health aspects |
| topic_facet | United States / Department of Defense Biological Warfare / prevention & control / United States Biological Warfare Agents / United States Civil Defense / methods / United States Military Medicine / methods / United States Toxicology MEDICAL / Toxicology Medizin Biological weapons Health aspects USA |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=123486 |
| work_keys_str_mv | AT committeeonacceleratingtheresearchdevelopmentandacquisitionofmedicalcountermeasuresagainstbiologicalwarfareagents acceleratingtheresearchdevelopmentandacquisitionofmedicalcountermeasuresagainstbiologicalwarfareagentsinterimreport |